4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-045100
Chief Financial Officer sold 12,000 shares at an average $86.74 ($1,040,919)
- Chief Financial Officer acquired 12,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-08-03 | Option exercise | +12,000 | $17.75 | $213,000 | 12,410 | D |
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-08-03 | Sale | −6,552 | $86.25 | $565,128 | 5,858 | D |
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-08-03 | Sale | −5,448 | $87.33 | $475,790 | 410 | D |
| Derivatives | |||||||
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2017-11-13 | Option exercise · Stock Option (Right to Buy) | −12,000 | 168,000 | D | ||
| Open-market sales · 12,000 sh · avg $86.74 · $1,040,919 | |||||||
Loading xslF345X03/doc4.xml…